Table 1 Summary of the immunological changes between ARE-Del+/− mice treated with ruxolitinib and control mice
Characteristic features of ARE-Del+/− mice | Control group | Treatment group |
|---|---|---|
Small bile duct damage | Aggravated | Attenuated |
Portal inflammation | Aggravated | Attenuated |
AMA | ↑ | ↓ |
Hepatic CD4+ T | ↑ | ↓ |
Hepatic CD8+ T | ↑ | ↓ |
Splenic CD4+ T | ↑ | ↓ |
Splenic CD8+ T | ↑ | ↓ |
Splenic Treg | ↓ | ↑ |
Splenic NK T | ↑ | ↓ |
Splenic GC B | ↑ | ↓ |
Splenic Tfh | ↑ | ↓ |
Liver macrophages | ↑/M1 | ↓/M2 |
PC macrophages | ↑/M1 | ↓/M2 |
Relative expression of inflammatory cytokines (IFNγ, IL-6, and TNFα) in liver tissues | ↑ | ↓ |
